Immunotherapy of type 1 diabetes mellitus

被引:0
作者
Krisztina, Arapovicsne Kiss [1 ]
Anna, Toth [1 ]
Laszlo, Schandl [1 ]
Zsofia, Kiss [2 ]
Gabor, Winkler [1 ,3 ]
Tibor, Kis Janos [1 ,4 ]
机构
[1] Eszak Budai Szent Janos Centrumkorhaz, Belgyogyaszat Diabetol 2, Budapest, Hungary
[2] Budai Irgalmasrendi Korhaz, Allergol & Immunol, Betegapolo Irgalmas Rend, Budapest, Hungary
[3] Elmeleti Egeszsegtudomanyi Int, Egeszsegtudomanyi Kar, Miskolc Egyet, Miskolc, Hungary
[4] Dios Arok 1-3, H-1125 Budapest, Hungary
关键词
type; 1; diabetes; prevention; immunotherapy; glutamic acid decarboxylase antibody; teplizumab; TH1; BIAS; T-CELLS; INTERVENTION; PREVENTION; SECRETION; TRIAL; ONSET;
D O I
10.1556/650.2024.33000
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Type 1 diabetes mellitus is an autoimmune disease with chronic progressive nature. The genetic, immunological, and initial metabolic abnormalities long precede the appearance of clinical symptoms, which brings up the possibility of delaying, preventing, or even reversing the development of the disease. Unfortunately, clinical trials aimed at the prevention of the disease did not bring resounding success for a long time. Recently, however, immunological treatment has reached the stage where the benefits of the intervention outweigh the risks associated with the treatment. Putting these options into daily practice, the possibility of delaying insulin treatment will reshape the current strategy of treating the disease and searching for high -risk patients with type 1 diabetes. The authors summarize the most essential knowledge about immunotherapy for the disease.
引用
收藏
页码:363 / 369
页数:7
相关论文
共 41 条
[1]   Functional diversity of helper T lymphocytes [J].
Abbas, AK ;
Murphy, KM ;
Sher, A .
NATURE, 1996, 383 (6603) :787-793
[2]   Emerging Anti-Diabetic Drugs for Beta-Cell Protection in Type 1 Diabetes [J].
Ajmal, Nida ;
Bogart, Maislin C. ;
Khan, Palwasha ;
Max-Harry, Ibiagbani M. ;
Nunemaker, Craig S. .
CELLS, 2023, 12 (11)
[3]  
Banting FG, 1922, CAN MED ASSOC J, V7, P141
[4]   Ingested IFN-α preserves residual β cell function in type 1 diabetes [J].
Brod, SA ;
Atkinson, M ;
Lavis, VR ;
Brosnan, PG ;
Hardin, DS ;
Orlander, PR ;
Nguyen, M ;
Riley, WJ .
JOURNAL OF INTERFERON AND CYTOKINE RESEARCH, 2001, 21 (12) :1021-1030
[5]   Current progress in stem cell therapy for type 1 diabetes mellitus [J].
Chen, Shuai ;
Du, Kechen ;
Zou, Chunlin .
STEM CELL RESEARCH & THERAPY, 2020, 11 (01)
[6]  
Diabetes Prevention Trial Type Stu, 2005, DIABETES CARE, V28, P1068
[7]   Immune response differs between intralymphatic or subcutaneous administration of GAD-alum in individuals with recent onset type 1 diabetes [J].
Dietrich, Fabricia ;
Barcenilla, Hugo ;
Tavira, Beatriz ;
Wahlberg, Jeanette ;
Achenbach, Peter ;
Ludvigsson, Johnny ;
Casas, Rosaura .
DIABETES-METABOLISM RESEARCH AND REVIEWS, 2022, 38 (03)
[8]   European Nicotinamide Diabetes Intervention Trial (ENDIT):: a randomised controlled trial of intervention before the onset of type 1 diabetes [J].
Gale, EAM ;
Bingley, PJ ;
Knip, M ;
Emmett, CL ;
Swankie, H ;
Fewell, S ;
Kearsey, P ;
Schober, E ;
Gorus, FK ;
Dupre, J ;
Mahon, JL ;
Profozic, V ;
Reimers, JI ;
Mandrup-Poulsen, T ;
Levy-Marchal, C ;
Jaeger, C ;
Bartsocas, C ;
Vazeou, A ;
Györko, M ;
Soltesz, G ;
Madacsy, L ;
Pastore, MR ;
Pozzilli, P ;
Dahl-Jorgensen, K ;
Joner, G ;
Kinalska, I ;
Mrozikiewicz, A ;
Vaykhonsky, Y ;
de Leiva, A ;
Martinez-Larrad, MT ;
Mauricio, D ;
Serrano-Rios, M ;
Ludvigsson, J ;
Schoenle, EJ ;
Yilmaz, MT ;
Carson, DJ ;
Tennet, H ;
Robertson, K ;
Gillespie, KM ;
Gillmor, H ;
Moore, WPT ;
Norcross, A ;
Williams, AJK ;
Dinesen, B ;
Kjellberg, S ;
Akelsen, HE ;
Thorsby, E ;
Undlien, DE ;
Collier, T ;
Hardy, P .
LANCET, 2004, 363 (9413) :925-931
[9]   Interventions in people newly diagnosed with type 1 diabetes mellitus [J].
Greenhill, Claire .
NATURE REVIEWS ENDOCRINOLOGY, 2023, 19 (05) :252-252
[10]   Diabetes mellitus and the intestinal microbiome [J].
Gyula, Tomasics ;
Laszlo, Schandl ;
Annamaria, Polyak ;
Gabor, Winkler .
ORVOSI HETILAP, 2023, 164 (25) :981-987